he company operates a regional clinical laboratory that offers diagnostic services to the New York, New Jersey and eastern Pennsylvania medical communities. The company’s clinical laboratory testing is utilized by physicians as an essential element in the delivery of healthcare services. Physicians use laboratory tests to assist in the detection, diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions. Clinical testing is performed on body fluids, such as blood and urine. Anatomic pathology testing is performed on tissues and other samples, such as human cells. The company offers a range of routine and esoteric clinical laboratory tests or procedures. These tests are frequently used in general patient care by physicians to establish or support a diagnosis, to monitor treatment or medication levels, or search for an otherwise undiagnosed condition. The company’s full service clinical laboratory in Farmingdale, New York contains an infrastructure that includes comprehensive information technology applications, logistics, client service and billing departments. Also, the company has a network of approximately 30 strategically located patient service centers and a full service phlebotomy department. Patient service centers collect from patients the specimens as requested by physicians. The company also operates a fully equipped STAT laboratory in New York City. Research and Development As of July 31, 2014, the company incurred costs of approximately $3.1 million for research and development activities. Sales and Marketing The company’s sales and marketing strategy for Enzo Life Sciences is to sell its life science products through: direct sales to end-users under the Enzo Life Sciences name, with direct recognition to its acquired brands; direct sales to end users under the Axxora electronic market place name; supply agreements with manufacturers; and distributors in major geographic markets. The company’s direct marketing and sales network includes fully-owned subsidiaries, a branch office in France, and a network of third party distributors in most other significant markets worldwide. The company markets the clinical laboratory services to a range of ordering physicians in the metro New York, New Jersey and eastern Pennsylvania region through its direct sales force who are supported by customer service and patient service representatives. Intellectual Property As of July 31, 2014, the company owned or licensed approximately 145 patents relating to products, methods and procedures resulting from its internal or sponsored research projects. Strategy Main elements of the company’s strategy involving three separate platforms include its ability to: using its core technology, launch new platform for molecular diagnostics; maximize resources by collaborating with others in research and commercialization activities; exploit marketing and distribution infrastructure; expand collaborations with major life sciences companies; apply innovative technology to various diseases mediated by cell signaling pathways, by the immune system, or, in advanced cases, gene therapy; and expand and protect intellectual property estate. Regulations The company’s business is and would continue to be subject to regulation under various state and federal environmental, safety and health laws, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act, and the Atomic Energy Act or their state law analogs. History Enzo Biochem, Inc. was founded in 1976.
enzo biochem inc (ENZ:New York)
527 Madison Avenue
New York, NY 10022
|NanoString Technologies Inc||$12.91 USD||+0.375|
|NeoGenomics Inc||$3.85 USD||-0.03|
|Psychemedics Corp||$15.55 USD||+0.15|
|Response Genetics Inc||$0.38 USD||-0.015|
|WaferGen Bio-systems Inc||$3.23 USD||+0.13|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact ENZO BIOCHEM INC, please visit www.enzo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.